Hypha Labs Inc. has appointed Craig Ellins as its Chief Science Officer, following the sale of its cannabis lab assets. With a background in founding and leading companies such as One World Pharma and GB Sciences, Ellins brings a wealth of experience in identifying and seizing early-stage opportunities in new markets.
Ellins is described by the company as a forward-thinker in emerging technologies and industries. His deep knowledge and understanding of the cannabis industry are seen as particularly valuable by Hypha Labs, as they believe the psilocybin sector will evolve similarly.
The appointment of Ellins as Chief Science Officer signifies Hypha Labs’ commitment to pushing the boundaries of innovation in the production of active ingredients found in functional mushrooms like psilocybin. His expertise and leadership in emerging markets are expected to drive the company’s success in this new and evolving industry landscape.